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Abstract The atrial natriuretic factor (ANF) gene is activated
in cardiac myocytes by Ras and its effector Raf. However, MEK,
the best-characterized Raf substrate, cannot efficiently activate
ANF suggesting that Raf uses a MEK-independent pathway to
activate ANF. By manipulating MEK and Raf activities so that
they are equally effective at activating ERK, we now demon-
strate that Raf activates at least two signaling pathways in
cardiac myocytes that regulate the ANF promoter ; the
MEKCERK pathway inhibits ANF gene expression while a
Raf-induced, MEK-independent pathway activates expression.
This mechanism may provide increased ability to regulate ANF
expression in response to hypertrophic stimuli.
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1. Introduction
During post-natal development, cardiac muscle cells grow
by hypertrophy rather than proliferation. Along with numer-
ous characteristic phenotypic changes, such as increased cell
size and protein synthesis, certain genes, such as the atrial
natriuretic factor (ANF), are expressed during hypertrophy
and are therefore considered hypertrophic markers [1].
Many di¡erent stimuli lead to hypertrophy, and several di¡er-
ent signal transduction pathways have been shown to regulate
expression of the ANF gene primarily using rat neonatal ven-
tricular myocytes as a model system. Treatment of these cells
with various hypertrophic agonists leads to many of the char-
acteristics associated with hypertrophy in vivo.
Mitogen-activated protein (MAP) kinases translate extra-
cellular signals into changes in gene expression. These path-
ways regulate gene expression and a¡ect cell growth, death
and/or di¡erentiation in many cell types [2,3]. The best char-
acterized MAP kinase pathways leading to ERK, JNK and
p38 activation have been implicated in the regulation of ANF
expression and other hypertrophic phenotypes in a large num-
ber of studies over recent years [4^20]. These studies have
mostly agreed on the stimulatory role of the ‘stress-induced’
MAP kinases, JNK and p38, in regulating ANF expression.
However, there have been con£icting conclusions regarding
the role of the ERK 1 and 2 MAP kinases that are activated
by the prototypical RasCRafCMEKCERK pathway in the
regulation of this promoter. A catalytically inactive ERK mu-
tant [7], antisense oligonucleotides that deplete ERK1 and
ERK2 [20], or MKP1, a phosphatase that inactivates the
ERKs (and other MAP kinases) [9,15], have all been shown
to inhibit ANF expression in response to various hypertrophic
stimuli. In addition it has been reported that active MEK, the
enzyme immediately upstream of the ERKs, is su⁄cient to
stimulate ANF expression [5]. These data are consistent
with a stimulatory role for the ERK pathway on the ANF
promoter. However, it has also been shown that ERK activa-
tion can be dissociated from ANF expression [16], and that
activation of MEK, and thus ERK activity, can actually in-
hibit ANF gene expression [9]. Furthermore, the MEK inhib-
itor PD98059 was unable to prevent ANF expression [16] and
has been shown to further stimulate ANF expression in some
situations [10,21]. These data are consistent with no stimula-
tory role and in fact an inhibitory role for the ERK pathway
on ANF expression. Thus, although we previously found that
active Raf is su⁄cient to stimulate ANF expression [8], it is
not clear whether Raf’s known downstream target, MEK, is
responsible for mediating Raf’s ability to stimulate ANF gene
expression.
To further investigate the mechanism through which Raf is
able to induce ANF expression, we separately manipulated
Raf and MEK activity in cardiac myocytes and monitored
the e¡ect on a bona ¢de target of the ERK pathway and
the ANF promoter. These experiments indicate that Raf acti-
vates the ANF promoter through a signal transduction path-
way that does not involve MEK and that increased MEK
activity inhibits Raf-induced ANF gene expression. Thus,
Raf utilizes at least one novel substrate to activate gene ex-
pression in cardiac myocytes while simultaneously activating
the ERK pathway, which counteracts this induction.
2. Materials and methods
2.1. Cell culture and transfections
All experiments were performed by calcium phosphate-mediated
transient transfection of primary neonatal rat ventricular myocytes.
Myocytes were prepared, cultured and transfected as previously de-
scribed [9,10,21] using the amounts of plasmid DNAs noted in the
¢gure legends for each experiment. Where required, the total amount
of plasmid in the transfection mix was kept constant by adding the
relevant empty expression vectors. Luciferase and L-galactosidase as-
says were performed with reagents from Promega (Madison, WI,
USA) or Tropix (Bedford, MA, USA) as described by the manufac-
turer. Transfection e⁄ciencies were normalized by dividing the lucif-
erase activity from each dish by the L-galactosidase activity from the
same dish. Data in each experiment are presented as the mean þ S.D.
of triplicates from a representative experiment. All experiments were
performed at least three times with di¡erent preparations of plasmids
and primary cells, producing qualitatively similar results.
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2.2. Plasmids
The activated MEK molecule (vN3/S218E/S222D MEK, also des-
ignated R4F) was provided by Natalie Ahn (University of Colorado,
Boulder, CO, USA). The estrogen-regulated Raf-1 expression vector
(pCEP4vRaf-1:ER) [8] was based on molecules provided by Martin
McMahon (UCSF, San Francisco, CA, USA) and expresses the kin-
ase domain of Raf-1 fused to the steroid-binding domain of the hu-
man estrogen receptor. The kinase activity of this molecule is depend-
ent on the addition of exogenous estradiol to the culture medium
[22,23].
The ERK2-MEK1 plasmid [24] was provided by Melanie Cobb
(UT Southwestern Medical School, Dallas, TX, USA). BXB-Raf-
MEK was constructed by replacing the ERK2 in the ERK2-MEK1
molecule with the kinase domain of Raf-1 (BXB-Raf). The ANF-
luciferase plasmids contained regions of the ANF promoter (as speci-
¢ed in Section 3) driving a luciferase reporter gene derived from pGL3
(Promega, Madison, WI, USA). Gal4:Elk-1 (pFA-Elk-1, from Stra-
tagene, La Jolla, CA, USA) contains a CMV-driven Gal4 DNA bind-
ing domain fused to the Elk-1 activation domain. Gal4:luciferase
(pFR-Luc, from Stratagene) contains ¢ve Gal4 binding elements driv-
ing a luciferase reporter gene. For luciferase assays, ANF-luciferase or
Gal4-luciferase reporters were co-transfected with a Rous sarcoma
virus (RSV)-L-galactosidase reporter plasmid (provided by Michael
Kapilo¡, Vollum Institute, Portland, OR, USA) that was used to
normalize transfection e⁄ciencies.
3. Results
3.1. Active MEK does not mimic the e¡ects of active Raf on
ANF gene expression
To determine whether MEK can mimic Raf activation of
the ANF promoter, we performed experiments with active
forms of these molecules. A constitutively active form of
MEK1 [25], referred to as R4F, contains a deletion of the
N-terminal regulatory domain and has two negatively charged
amino acids replacing serines on which Raf phosphorylates
and activates MEK. vRaf-1:ER is an estradiol-inducible
form of Raf-1 whose enzymatic activity can be controlled
by titrating estradiol into the culture media [22,23]. We per-
formed transient transfections in primary cardiac myocytes
with these molecules to determine their ability to activate
33003ANF:luc, a luciferase reporter gene driven by base
pairs 31 to 33003 of the ANF promoter. In parallel experi-
ments, Gal4:Elk-1 was used to induce expression from Gal4:
luc. Gene expression from this molecule measures activity
through the RafCMEKCERK cascade. By separately titrat-
ing estradiol concentrations to induce vRaf-1:ER and intro-
ducing di¡erent amounts of active MEK into the cells, it is
possible to regulate the amount of ERK activity so that equiv-
alent amounts of active ERK are stimulated by either Raf or
MEK.
A dose response was performed to determine whether
equivalent signaling to ERK from Raf and MEK, as meas-
ured by Gal4:luc expression, has equivalent e¡ects on
33003ANF:luc expression. In control experiments, treatment
of cells with estradiol failed to activate reporter expression in
the absence of vRaf-1:ER (data not shown). Fig. 1A shows
that at their highest doses, R4F and vRaf-1:ER have similar
abilities to activate ERK. However, Fig. 1B indicates that
these doses of MEK cannot mimic that ability of Raf to
activate 33003ANF:luc. In multiple experiments using di¡er-
ent preparations of primary cells, the ability of vRaf-1:ER to
activate 33003ANF:luc varied from 2.5-fold to 7-fold be-
tween experiments. In some experiments (such as that shown
in Fig. 1B but not the experiment in Fig. 2A), we observed
some activation of 33003ANF:luc by active MEK. However,
for any particular preparation of cells, Raf was always more
e¡ective than MEK at activating 33003ANF:luc even when
activation of Gal4:Elk-1, a bona ¢de target of the ERK path-
way was equivalent. Thus, equal amounts of signaling to
ERK by Raf and MEK have di¡erent e¡ects on ANF gene
expression with Raf being more e⁄cient at inducing the ANF
promoter.
3.2. Increased MEK activity inhibits Raf-dependent activation
of 33003ANF:luc
We previously found that active MEK inhibits PE-induced
expression of 33003ANF:luc [9]. To determine if increased
MEK activity could also inhibit Raf-induced 33003ANF:luc
expression, we performed experiments using vRaf-1:ER and
R4F simultaneously. Dose response curves were performed
using increasing concentrations of estradiol, at three di¡erent
concentrations of R4F. Once again Gal4:Elk-1/Gal4:luc con-
structs were included in parallel to monitor the amount of
ERK activity in each case. The results are shown in Fig. 2A.
With no added MEK, increasing concentrations of es-
tradiol led to increasing activation of both Gal4:Elk-1 and
Fig. 1. MEK cannot mimic Raf activation of 33003ANF:luc. A:
Empty expression plasmid plus or minus increasing amounts of
R4F (as indicated and supplemented with empty expression plasmid
to total 3 Wg), or 3 Wg vRaf-1:ER with increasing amounts of estra-
diol (as indicated, with the same total amount of ethanol vehicle in
each instance), were transfected along with RSVLgal and the Ga-
l4:Elk-1/Gal4:luc reporter system. B: Cells were transfected and
treated the same as in (A) but with the 33003ANF:luc reporter.
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33003ANF:luc as expected. However, at 0 nM estradiol, i.e.
no vRaf-1:ER activity, increasing amounts of MEK led to a
dose-responsive activation of Gal4:Elk-1, but no overall acti-
vation of 33003ANF:luc. Thus, as before, active MEK was
able to induce Gal4:luc through Gal4:Elk-1 but was unable to
induce the ANF promoter. Additionally, while increasing
amounts of MEK potentiated the ability of Raf to activate
Gal4:Elk-1, they led to a dose-dependent inhibition of Raf-
induced 33003ANF:luc expression. These data indicate that
MEK can inhibit Raf-dependent activation of 33003ANF:luc
and further suggest that increased MEK activity and thus
increased ERK activity is not responsible for Raf activation
of 33003ANF:luc.
If MEK is in fact acting as an inhibitor of ANF expression,
then blocking MEK activation should increase Raf-dependent
activation of ANF. To test this hypothesis, we performed
experiments with vRaf-1:ER and increasing amounts of the
MEK inhibitor PD98059. Fig. 2B shows two separate experi-
ments with PD98059. Experiment 1 showed a slight increase
in Raf activation of ANF in the presence of PD98059. Experi-
ment 2 showed a more pronounced increase in Raf activation
of ANF at lower concentrations of PD98059, then a return to
normal levels of Raf activation at higher concentrations. At
the highest concentrations, the PD inhibitor was becoming
insoluble explaining the variability between experiments.
These data indicate that the MEK inhibitor does not prevent
Raf-dependent activation of the promoter and even potenti-
ates activation supporting the view that MEK and ERK ac-
tivity is primarily a negative in£uence on the ANF promoter.
3.3. Raf-dependent activation and MEK-dependent inhibition
are achieved through separate DNA elements in the ANF
promoter
To test whether Raf activation and MEK inhibition of the
Fig. 2. MEK inhibits Raf-dependent activation of ANF:luc. A:
Empty expression plasmid plus or minus increasing amounts of
R4F (as indicated and supplemented with empty expression plasmid
to total 2 Wg), were transfected along with 1 Wg vRaf-1:ER,
RSVLgal, and with either Gal4:Elk-1/Gal4:luc or 33003ANF:luc.
At each amount of R4F, three di¡erent concentrations of estradiol
were added to the media (as indicated, with the same addition of
ethanol vehicle in each instance). B: Cells were transfected with
vRaf-1:ER and 33003ANF:luc and treated with either vehicle
alone or 10 nM estradiol plus or minus increasing amounts of
PD98059 (as indicated).
Fig. 3. Raf-dependent activation and MEK-dependent inhibition are
achieved through separate DNA elements in the ANF promoter. A:
Cells were transfected with vRaf-1:ER (treated with either 100 nM
estradiol or the same amount of ethanol vehicle), RSVLgal, and ei-
ther 33003ANF:luc or 3672ANF:luc (as indicated). B: Empty ex-
pression plasmid plus or minus 100 WM phenylephrine (PE) or in-
creasing amounts of R4F (as indicated and supplemented with
empty expression plasmid to make the total 3 Wg) were transfected
with RSVLgal and either 33003ANF:luc or 3672ANF:luc.
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promoter are mediated through the same DNA elements, we
tested the ability of Raf to activate 3672ANF:luc, a luciferase
reporter gene driven by base pairs 31 to 3672 of the ANF
promoter. Fig. 3A shows that Raf can activate 33003AN-
F:luc but not 3672ANF:luc. This result indicates that
DNA sequences required for Raf stimulation of the promoter
lie between base pairs 3672 and 33003 in the ANF promoter.
To test if active MEK could still inhibit 3672ANF:luc ex-
pression, we treated cells with 100 WM PE (an e⁄cient inducer
of both 33003ANF:luc and 3672ANF:luc expression) and
performed a dose response with MEK. The results are shown
in Fig. 3B. As expected, MEK alone did not signi¢cantly
activate either 33003ANF:luc or 3672ANF:luc, while PE
alone activated both 33003ANF:luc and 3672ANF:luc to
a similar extent. As previously demonstrated [9], increasing
amounts of MEK led to inhibition of 33003ANF:luc expres-
sion. The same results were observed using 3672ANF:luc
indicating that DNA sequences that are required for MEK-
dependent inhibition of gene expression, are located down-
stream of 3672ANF. These results demonstrate that within
the ANF promoter, DNA sequences that are required for
Raf-dependent activation are separate from sequences that
are su⁄cient for MEK-dependent inhibition.
3.4. A Raf molecule that preferentially signals to MEK cannot
activate 33003ANF:luc
If Raf is indeed activating the ANF promoter via a MEK-
independent signaling pathway, a Raf molecule that preferen-
tially activates MEK rather than other substrates should be
compromised in its ability to stimulate ANF but should still
be able to e⁄ciently activate ERK-induced transcription. To
construct such a molecule we modi¢ed the ERK2-MEK1 fu-
sion protein that was constructed by Robinson et al. [24] by
inserting an active form of Raf-1 (BXB-Raf, which has a
deletion of the N-terminal regulatory domain) in place of
ERK2 in the ERK2-MEK1 fusion protein, thereby creating
a BXB-Raf-MEK fusion protein. This molecule tethers an
active Raf molecule to the wild-type MEK1 protein and
thus creates a Raf molecule that preferentially activates
MEK rather than other potential Raf substrates. We per-
formed a dose response curve with this fusion molecule and
asked if it was able to activate Gal4:Elk-1 and 33003AN-
F:luc.
Fig. 4A shows that increasing amounts of BXB-Raf-MEK
generate a dose responsive increase in Gal4:Elk-1 activation
such that 1000^3000 ng of BXB-Raf-MEK activates ERK to
the same extent as estradiol-stimulated vRaf-1:ER. Fig. 4B
shows that vRaf-1:ER activates 33003ANF:luc. However,
increasing amounts of BXB-Raf-MEK do not lead to any
signi¢cant activation of 33003ANF:luc. Thus although the
Raf molecule that preferentially activates MEK and vRaf-
1:ER (which is able to phosphorylate all potential Raf sub-
strates) were equally e¡ective at stimulating Gal4:Elk-1, only
vRaf-1:ER was able to activate ANF. These data indicate
that the ability of Raf to stimulate the ANF promoter is
not due to its ability to activate MEK.
4. Discussion
In this study we showed that Raf activates the hypertrophic
marker gene ANF in cardiac myocytes through a MEK-inde-
pendent signal transduction pathway. This conclusion is based
upon several lines of evidence. First, we separately manipu-
lated Raf and MEK activities so that they were equally e¡ec-
tive at inducing transcription from a bona ¢de target of the
ERK pathway yet found that only Raf was e¡ective at induc-
ing ANF promoter-driven reporter gene expression (Fig. 1).
Second, we constructed a Raf molecule that is preferentially
able to activate only one substrate, MEK, and found that it is
able to e⁄ciently activate ERK targets but not the ANF pro-
moter (Fig. 4). In addition, we showed (Fig. 2A) that increas-
ing MEK activity could inhibit Raf-induced ANF expression,
while inhibition of MEK further potentiates Raf-induced ac-
tivation (Fig. 2B). This result suggested that not only does
Raf activate the promoter via MEK-independent signals, the
simultaneous activation of the ERK pathway by Raf actually
inhibits ANF expression. Previously, we showed that the
ERK pathway inhibits ANF expression in response to phenyl-
ephrine, activated Gq or active MEKK1 [9,10,21]. Thus ANF
expression is regulated by competing positive and negative
stimuli that are simultaneously induced by MAP kinase kinase
kinases such as Raf or MEKK1.
These competing signals are regulated through separate
DNA sequences in the promoter. We found that Raf could
activate 33003ANF:luc, but not 3672ANF:luc (Fig. 3).
Therefore, Raf activation of ANF requires DNA sequences
Fig. 4. A Raf molecule that preferentially activates MEK cannot ac-
tivate 33003ANF:luc. A: Cells were transfected with either vRaf-
1:ER or increasing amounts of BXB-Raf-MEK (as indicated and
supplemented with empty expression plasmid to make the total
3 Wg), RSVLgal, and Gal4:Elk-1/Gal4:luc. Cells transfected with
vRaf-1:ER were treated with either 100 nM estradiol or the same
amount of ethanol vehicle. B: Cells were treated as in (A) but with
33003ANF:luc reporter.
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upstream of 3672ANF. However, MEK was able to inhibit
PE activation of 3672ANF:luc in a similar manner to that
demonstrated with 33003ANF:luc. Although sequences be-
tween 3672 and 33003 are required for Raf-dependent in-
duction, we were unable to obtain Raf-induced expression
when these sequences were fused behind a heterologous pro-
moter (data not shown). Further deletion analysis indicates
that no single deletion between 3672 and 33003 results in
loss of expression (data not shown). These data suggest that
the mechanism of activation by the Raf-dependent signal is
complex, perhaps requiring multiple DNA sequences and the
native ANF promoter. It has been suggested that the ANF
promoter might require formation of an enhancesome-like
structure for proper activation [26,27]. Our data are consistent
with the idea that the ultimate targets of the Raf-induced
signaling pathway only induce transcription in such a context.
In some experiments, we observed modest activation of
ANF by MEK (e.g. see Fig. 1B). Although this implies a
stimulatory role for MEK (as suggested by Gillespie-Brown
et al. [5]) Raf was always more e¡ective than MEK at activat-
ing 33003ANF:luc even when activation of Gal4:Elk-1, a
single, bona ¢de target of the ERK pathway was equivalent.
One way to reconcile all the data from our group and others
would be if there was a requirement for some ERK activity to
allow ANF activation. In this case, highly e⁄cient ERK in-
hibition might be incompatible with ANF activation via other
signaling pathways. In some experiments (see Fig. 2B) inhib-
ition of MEKCERK signaling by PD98059 led to a dose
responsive increase in Raf activation of ANF at lower con-
centrations, but ANF expression was diminished at higher
concentrations of the inhibitor supporting this hypothesis. A
complicating factor in the interpretation of such experiments
is that the inhibitor was becoming insoluble at the higher
concentrations. Such limitations make it di⁄cult to conclu-
sively test the hypothesis.
Although there have been several suggestions that Raf
might have physiological substrates other than MEK [28^
30], there are few examples where Raf is thought to alter
gene expression via a MEK-independent pathway. The clear-
est example where this is the case comes from Rosner and
colleagues [31,32]. These investigators showed that Raf could
activate a protein kinase that is distinct from ERK1 or ERK2,
that is able to phosphorylate and activate Elk-1 on the same
sites as ERK1 and ERK2 [31]. The ANF promoter clearly
cannot be activated solely by Elk-1 since we would expect
that MEK, which is an e⁄cient Elk-1 activator in our cells,
would then be able to activate ANF. However, it is possible
that the kinase that was discovered by Rosner and colleagues
or a similar molecule is also able to activate other transcrip-
tion factors in addition to Elk-1 that contribute to ANF acti-
vation. It will be possible to test this hypothesis when this
kinase is further characterized.
In conclusion, our data suggest that the MEK/ERK path-
way is not primarily responsible for Raf-dependent activation
of ANF and in fact plays a negative role in ANF gene ex-
pression. Therefore, Raf activates at least two signaling path-
ways that compete against each other to regulate the ANF
promoter. Similar competing pathways arise when active
MEKK1 induces the ANF promoter [10]. Further complexity
in the regulation of the ANF promoter is indicated by the fact
that a low-a⁄nity serum response element controls the activ-
ity of multiple transcription factors at other sites via a mech-
anism that is reminiscent of enhancesome-like activity [26].
Together, these data imply that ANF expression in hypertro-
phic heart cells has to be very tightly regulated. A possible
explanation for this conclusion comes from a recent study by
Silberbach and colleagues [33] who showed that ANF itself
inhibits hypertrophy by directly activating the MEKCERK
pathway without activating Raf or other MAP kinase path-
ways such as JNK or p38. These ¢ndings in combination with
our data imply that a delicate balance of ANF gene expres-
sion is required to maintain an optimal level of hypertrophy.
Thus, as MAP kinase kinase kinases such as Raf or MEKK1
are activated by hypertrophic stimuli, this will lead to expres-
sion of ANF perhaps via JNK and p38-dependent signals
[6,10,14] or the MEK-independent pathway that is shown
here. Then, as ANF expression exceeds a threshold, a feed-
back loop will be initiated via the ANF receptor and cGMP-
dependent signaling leading to MEK/ERK activation and
subsequent inhibition of the hypertrophic phenotype [33]. In
this scenario ANF-dependent activation of MEK should be
e¡ectively similar to our arti¢cial stimulation of MEK and
would therefore down-regulate ANF expression. This e¡ect
could be counteracted by a sustained hypertrophic stimulus
that was still able to activate Raf or MEKK1 and the MEK-
independent pathways that stimulate ANF expression. In this
manner, the level of expression of ANF that is achieved
through the complex interacting pathways that we have iden-
ti¢ed may serve as a ‘rheostat’ to regulate the extent and
maintenance of the hypertrophic response.
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